Arcutis Biotherapeutics, Inc. (ARQT) has announced the completion of enrollment in its INTEGUMENT-INFANT Phase 2 trial, which is evaluating ZORYVE (roflumilast) cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. Atopic dermatitis, a common form of eczema, affects nearly 9.6 million children in the U.S., with up to 60% developing symptoms in their first year of life. The disease often presents as an intensely itchy rash that can disrupt sleep and daily activ ...